Pulmonary hypertension and vascular oxidative damage in cigarette smoke exposed eNOS-/- mice and human smokers

Inhalation Toxicology

Volumn 24, Issue 11, 2012, Pages 732-740

  Wright, J L ^a   Zhou, S ^a   Churg, A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cigarette smoke; COPD; Nitrotyrosine; Pulmonary hypertension

Indexed keywords

3 NITROTYROSINE; CIGARETTE SMOKE; INDUCIBLE NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ARTERY PRESSURE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; HYPERTENSION, PULMONARY; LUNG; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; SMOKING; TYROSINE;

ANIMALIA; MUS;

EID: 84866089884     PISSN: 08958378     EISSN: 10917691     Source Type: Journal    
DOI: 10.3109/08958378.2012.715698     Document Type: Article

References (39)

1. Barberà JA, Blanco I. 2009. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: Advances in pathophysiology and management. Drugs 69:1153-1171.
2. Barnes PJ. 1990. Reactive oxygen species and airway inflammation. Free Radic Biol Med 9:235-243.
3. Brindicci C, Ito K, Torre O, Barnes PJ, Kharitonov SA. 2009. Effects of aminoguanidine, an inhibitor of inducible nitric oxide synthase, on nitric oxide production and its metabolites in healthy control subjects, healthy smokers, and COPD patients. Chest 135:353-367.
4. Celli BR. 2006. Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. Proc Am Thorac Soc 3:58-65.
5. Croxton TL, Weinmann GG, Senior RM, Hoidal Jr. 2002. Future research directions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 165:838-844.
6. Csiszar A, Podlutsky A, Wolin MS, Losonczy G, Pacher P, Ungvari Z. 2009. Oxidative stress and accelerated vascular aging: Implications for cigarette smoking. Front Biosci 14:3128-3144.
7. Demiryürek AT, Karamsetty MR, McPhaden AR, Wadsworth RM, Kane KA, MacLean MR. 2000. Accumulation of nitrotyrosine correlates with endothelial NO synthase in pulmonary resistance arteries during chronic hypoxia in the rat. Pulm Pharmacol Ther 13:157-165.
8. Doescher MP, Jackson JE, Jerant A, Gary Hart L. 2006. Prevalence and trends in smoking: A national rural study. J Rural Health 22:112-118.
9. Elwing J, Panos RJ. 2008. Pulmonary hypertension associated with COPD. Int J Chron Obstruct Pulmon Dis 3:55-70.
10. Fagan KA, Tyler RC, Sato K, Fouty BW, Morris KG Jr, Huang PL, McMurtry IF, Rodman DM. 1999. Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. Am J Physiol 277:L472-L478.
11. Fagan KA, McMurtry I, Rodman DM. 2000. Nitric oxide synthase in pulmonary hypertension: Lessons from knockout mice. Physiol Res 49:539-548.
12. Förstermann U. 2010. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 459:923-939.
13. Förstermann U, Münzel T. 2006. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113:1708-1714.
14. Gielis JF, Lin JY, Wingler K, Van Schil PE, Schmidt HH, Moens AL. 2011. Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders. Free Radic Biol Med 50:765-776.
15. Grassi D, Desideri G, Ferri L, Aggio A, Tiberti S, Ferri C. 2010. Oxidative stress and endothelial dysfunction: Say NO to cigarette smoking! Curr Pharm Des 16:2539-2550.
16. Halbower AC, Mason RJ, Abman SH, Tuder RM. 1994. Agarose infiltration improves morphology of cryostat sections of lung. Lab Invest 71:149-153.
17. Hida W, Tun Y, Kikuchi Y, Okabe S, Shirato K. 2002. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: Recent advances in pathophysiology and management. Respirology 7:3-13.
18. Hoeper MM. 2008. Treating pulmonary hypertension in COPD: where do we start? Eur Respir J 32:541-542.
19. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. 1995. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377:239-242.
20. Jankov RP, Lewis P, Kantores C, Ivanovska J, Xu EZ, Van Vliet T, Lee AH, Tanswell AK, McNamara PJ. 2010. Peroxynitrite mediates rightventricular dysfunction in nitric oxide-exposed juvenile rats. Free Radic Biol Med 49:1453-1467.
21. Labonté J, Brochu I, Simard E, D'Orléans-Juste P. 2008. Distinct modulation of the endothelin-1 pathway in iNOS-/- and eNOS-/ mice. Can J Physiol Pharmacol 86:516-525.
22. MacNee W, Rahman I. 2001. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med 7:55-62.
23. Magee F, Wright JL, Wiggs BR, Paré PD, Hogg JC. 1988. Pulmonary vascular structure and function in chronic obstructive pulmonary disease. Thorax 43:183-189.
24. Markewitz BA, Michael JR, Kohan DE. 1997. Endothelin-1 inhibits the expression of inducible nitric oxide synthase. Am J Physiol 272:L1078-L1083.
25. Naeije R. 2005. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2:20-22.
26. Naeije R, Barberà JA. 2001. Pulmonary hypertension associated with COPD. Crit Care 5:286-289.
27. Pryor WA, Stone K. 1993. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci 686:12-27; discussion 27.
28. Rahman I, Biswas SK, Kode A. 2006. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 533:222-239.
29. Seimetz M, Parajuli N, Pichl A, Veit F, Kwapiszewska G, Weisel FC, Milger K, Egemnazarov B, Turowska A, Fuchs B, Nikam S, Roth M, Sydykov A, Medebach T, Klepetko W, Jaksch P, Dumitrascu R, Garn H, Voswinckel R, Kostin S, Seeger W, Schermuly RT, Grimminger F, Ghofrani HA, Weissmann N. 2011. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 147:293-305.
30. Sin DD, Stafinski T, Ng YC, Bell NR, Jacobs P. 2002. The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med 165:704-707.
31. Steudel W, Ichinose F, Huang PL, Hurford WE, Jones RC, Bevan JA, Fishman MC, Zapol WM. 1997. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res 81:34-41.
32. Tabima DM, Frizzell S, Gladwin MT. 2012. Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic Biol Med 52:1970-1986.
33. Traver GA, Cline MG, Burrows B. 1979. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am Rev Respir Dis 119:895-902.
34. Vanoirbeek JA, Rinaldi M, De Vooght V, Haenen S, Bobic S, Gayan-Ramirez G, Hoet PH, Verbeken E, Decramer M, Nemery B, Janssens W. 2010. Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases. Am J Respir Cell Mol Biol 42:96-104.
35. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. 1981. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 36:752-758.
36. Wright JL, Churg A. 1991. Effect of long-term cigarette smoke exposure on pulmonary vascular structure and function in the guinea pig. Exp Lung Res 17:997-1009.
37. Wright JL, Tai H, Churg A. 2006. Vasoactive mediators and pulmonary hypertension after cigarette smoke exposure in the guinea pig. J Appl Physiol 100:672-678.
38. Wright JL, Zhou S, Churg A. 2010. Late intervention with a statin reverses cigarette smoke induced pulmonary arterial dysfunction and pulmonary hypertension in the guinea pig. A J Resp Crit Care Med 181:A3884.
39. Yao H, Rahman I. 2011. Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol Appl Pharmacol 254:72-85.